Disclaimer
The information contained in this section of the website contains information relating to an offer from Implantica AG (the "Company") to the public to subscribe for Swedish Share Depositary Receipts in the Company in connection with the admission to trading of the Company's Swedish Share Depositary Receipts on Nasdaq First North Growth Market Premier in Stockholm. This information may not be accessed by residents of certain countries based on applicable securities law regulations.
The information contained in this section of the website is restricted and is not for release, publication or distribution, directly or indirectly, in whole or in part in, into or from the United States of America (including its territories and possessions), any state of the United States including the District of Columbia, Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, Switzerland, South Africa, South Korea or any jurisdiction where to do so might constitute a violation of the local securities laws or regulations of such jurisdiction. Click here to return to the homepage
The information contained in this section of the website is restricted and is not for release, publication or distribution, directly or indirectly, in whole or in part in, into or from the United States of America (including its territories and possessions), any state of the United States including the District of Columbia, Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, Switzerland, South Africa, South Korea or any jurisdiction where to do so might constitute a violation of the local securities laws or regulations of such jurisdiction. Click here to return to the homepage
Disclaimer
The information contained in this section of the website contains information relating to an offer from Implantica AG (the "Company") to the public to subscribe for Swedish Share Depositary Receipts in the Company in connection with the admission to trading of the Company's Swedish Share Depositary Receipts on Nasdaq First North Growth Market Premier in Stockholm. This information may not be accessed by residents of certain countries based on applicable securities law regulations.
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, WHOLLY OR PARTLY, IN THE United States of America (including its territories and possessions), any state of the United States INCLUDING the District of Columbia, Australia, CANADA, Hong Kong, Japan, New Zealand, Singapore, Switzerland, South Africa, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW.
This website and the information contained herein is not intended for, and may not be accessed by, or distributed or disseminated to, persons resident or physically present in the United States of America (including its territories and possessions), any state of the United States including the District of Columbia (the "United States"), Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, Switzerland, South Africa, South Korea and do not constitute an offer to sell or the solicitation of an offer to purchase or acquire, any securities of the Company in any of the above mentioned jurisdictions or in any other jurisdiction in which such offer or solicitation would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. The securities of the Company referred to on this website have not been, and will not be, registered under the Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act.
All persons residing outside of the above mentioned jurisdictions who wish to access the documents contained on this website should first ensure that they are not subject to local laws or regulations that prohibit or restrict their right to access this website, or require registration or approval for any acquisition of securities by them. The Company assumes no responsibility if there is a violation of applicable law and regulations by any person.
If you are not permitted to view materials on this website or are in any doubt as to whether you are permitted to view these materials, please exit this website.
Access to electronic versions of these materials is being made available on this website by the Company in good faith and for information purposes only.
By clicking "Confirm" you confirm and certify that:
- You are not a resident of or physically present in any of the above jurisdictions or any other restricted jurisdiction and are not a U.S. person (as defined in Regulation S under the Securities Act); and
- you are either:
- a resident of, or physically present in, Sweden;
- if resident or physically present in a Member State of the European Economic Area other than Sweden, a qualified investor as defined in Regulation (EU) 2017/1129 of the European parliament and of the council; or
- otherwise authorized to access this information pursuant to applicable laws or regulations.
I have read, understand and agree to comply with all of the restrictions set forth above.
Access to this information is limited to persons resident and physically present in Sweden and to authorized persons who are resident and physically present in other jurisdictions outside Australia, Hong Kong, Japan, Canada, New Zealand, South Africa or the United States of America.
IPO
A SHORT BACKGROUND INFORMATION
Implantica is a medtech group with operations within the implantable medical device and eHealth markets. The Company’s lead product RefluxStopTM is a passive CE-marked implant for prevention of gastroesophageal reflux. Current surgical gastroesophageal reflux disease ("GERD") treatments function by compressing the food passageway, giving rise to various adverse complications. RefluxStopTM has a completely different design thesis, which achieves better results without the complications associated with existing surgical GERD treatments. The Company believes RefluxStopTM has the potential to spur a paradigm shift in GERD treatments. In addition to RefluxStopTM, the Company has an extensive product pipeline that is expected to further support Implantica’s growth in the coming years.
The Group was founded in 2015 by Dr. Peter Forsell, principal shareholder and Chief Executive Officer (CEO), by injecting at cost two platform technologies as well as products and patents. It took eight years to develop the platform technologies, the wireless energising and eHealth platforms, and after scanning the whole body for suitable product applications, a large patent portfolio of over 1,000 patent cases was created. During a three-year period over 70 engineers analysed over 300 individual inventions, conducting market and product analysis and prototyping to select 40 viable implant product candidates. This brings a platform for further long-term growth potential, however, in addition to the commercialisation of RefluxStopTM, which is already on the market, the company is strictly focusing on launching three more products, UriControl®, UriRestore® and AppetiteControl™.
In their previous business, Dr. Forsell and Stephan Siegenthaler, Chief Sales & Marketing Officer, were co-founders and executive management members of Obtech Medical AG (“Obtech”) that brought the Swedish Adjustable Gastric Band (“SAGB”) – an innovative gastric band developed by Dr. Forsell – to market. In 2002 Obtech was sold to Johnson & Johnson for CHF 175 million before US FDA approval. Since the sale of Obtech, Dr. Forsell has injected over EUR 85.4 million in Implantica.
Implantica’s board of directors believes the Company has a promising future with the CE-marked RefluxStopTM under commercialization, an attractive product pipeline and substantial revenue potential.
Press releases
Video presentations
Implantica Presentation August 2020 7 min, Swedish
Implantica Presentation August 2020 7 min, English
A summary of the offer
| SUMMARY OF THE OFFER | |
|---|---|
| Price per SDR: | 65.00 SEK |
| Application period for the public in Sweden: | 8 September—16 September 2020 |
| Application period for institutional investors: | 8 September—16 September 2020 |
| Intention to float: | 31 August 2020 |
| Prospectus published: | 7 September 2020 |
| First day of trading: | 21 September 2020 |
| Settlement date: | 23 September 2020 |
Note: All dates are on or about.
| FINANCIAL CALENDAR | |
|---|---|
| Interim report for the period 1 January – 30 September 2020 | 18 November 2020 |
| Year-End report 2020 | 25 February 2021 |
| Annual General Meeting 2021 | 16 April 2021 |
Investor relations contact
Nicole Pehrsson
VP Operations & Investor Relation
+41 (0)79 335 09 49
nicole.pehrsson@implantica.com
Certified advisor
FNCA Sweden AB
www.fnca.se